Israel - English - Ministry of Health

megapharm ltd - collagenase clostridium histolyticum - powder and solvent for solution for injection - collagenase clostridium histolyticum 0.9 mg/vial - collagenase clostridium histolyticum - xiapex is indicated for the treatment of dupuytren’s contracture in adult patients with a palpable cord.the treatment of adult men with peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

European Union - English - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - antineoplastic agents - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

European Union - English - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - eftrenonacog alfa - hemophilia b - vitamin k and other hemostatics, blood coagulation factors - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

European Union - English - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - immunosuppressants - rheumatoid arthritis (ra)kineret is indicated in adults for the treatment of the signs and symptoms of ra in combination with methotrexate, with an inadequate response to methotrexate alone.covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml.periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret should be given in combination with colchicine, if appropriate.still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids.kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).

United States - English - NLM (National Library of Medicine)

swedish orphan biovitrum ab (publ) - palivizumab (unii: dq448mw7ks) (palivizumab - unii:dq448mw7ks) - synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in pediatric patients: - with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of rsv season, - with bronchopulmonary dysplasia (bpd) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of rsv season, - with hemodynamically significant congenital heart disease (chd) and who are 24 months of age or younger at the beginning of rsv season [see clinical studies (14) ]. limitations of use: the safety and efficacy of synagis have not been established for treatment of rsv disease [see warnings and precautions (5.4)] . synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to synagis [see warnings and precautions (5.1) ]. risk summary synagis is not indicated for use in females of reproductive po

European Union - English - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).

Canada - English - Health Canada

bioenergy inc. - ascorbic acid - tablet (extended-release) - 1g - ascorbic acid 1g - vitamin c

Canada - English - Health Canada

bioenergy inc. - ascorbic acid - tablet (extended-release) - 500mg - ascorbic acid 500mg - vitamin c

Canada - English - Health Canada

bioenergy inc. - inositol; dl-methionine; nicotinic acid; thiamine hydrochloride; pyridoxine hydrochloride; choline bitartrate - tablet (extended-release) - 1g; 400mg; 400mg; 100mg; 100mg; 1g - inositol 1g; dl-methionine 400mg; nicotinic acid 400mg; thiamine hydrochloride 100mg; pyridoxine hydrochloride 100mg; choline bitartrate 1g - vitamin b complex

Canada - English - Health Canada

bioenergy inc. - choline bitartrate; inositol; d-pantothenic acid (calcium d-pantothenate); folic acid; biotin; thiamine hydrochloride; vitamin b2; pyridoxine hydrochloride; vitamin b12; nicotinamide - tablet (extended-release) - 100mg; 30mg; 100mg; 800mcg; 100mcg; 75mg; 43mg; 100mg; 300mcg; 200mg - choline bitartrate 100mg; inositol 30mg; d-pantothenic acid (calcium d-pantothenate) 100mg; folic acid 800mcg; biotin 100mcg; thiamine hydrochloride 75mg; vitamin b2 43mg; pyridoxine hydrochloride 100mg; vitamin b12 300mcg; nicotinamide 200mg - vitamin b complex